Guest View
User: Pass: | become a member
Posts Tagged ‘drugs’

Is It Time To Put A Fork In The BATFE?

Watch the video below too.  In this case, felony murder rules would not likely apply because there was no intent. It sounds more like "Project Gunwalker" was a disasterous plan from the beginning that worked out, not surprisingly, disasterously. – Ilene 

Courtesy of Karl Denninger, The Market Ticker 

I’ve been following the Project Gunwalker story for a while.

For those who are not familiar with it, the story line is this: The BATFE, that’s right – the Federal Government - has been intentionally allowing "straw sales" of rifles and pistols to go through and then letting those guns be transported to Mexico.

These are sales where the person doing the buying isn’t the actual intended owner of the weapon.  These guns are often bought in bulk, many at a time.  It’s not illegal to buy a lot of guns, even all at once, but it is a felony to buy them for someone else.

Anyway, BATFE was allegedly allowing this to go on and approving sales they knew were bogus.  Starting in 2009 several gun stores started getting suspicious – they were having people come in and paying with cash – sometimes with cash in paper bags – for multiple guns at once.  Specifically, it is alleged that over five hundred AK-47 semi-automatic rifles and over 2,500 weapons in total, including rifles and pistols, were purchased in this manner.

The claim is made that the BATFE literally watched the sales happen, each checked through NICS’ "background check", each approved, despite being alerted by the gun store owners that the sales were suspicious. 

The stores were told to proceed with the sales intentionally.

Let me repeat this: The allegation is that the BATFE intentionally allowed these weapons to be purchased despite knowing they were fraudulent straw purchases and then allowed them to be unlawfully transported into Mexico where they were delivered to various Mexican outlaws – including drug gangs.

Remember, we’ve been told that a lot of guns that Mexican drug lords are using are coming from the US?  Well, no kidding, they are, if this allegation is correct: Our own government was knowingly allowing them to be purchased and illegally transported across the border.

That’s bad.

What’s worse is this:

Then, Border Patrol Agent Brian Terry was murdered. The serial numbers on the two assault rifles found at the scene matched two rifles ATF watched Jaime Avila buy in Phoenix nearly a year before. Officials won’t answer whether the bullet that killed


continue reading


Tags: , , , , , , , , , ,




Fever to Harness RNA Interference Cools – NYTimes.com

Drugmakers’ Fever for the Power of RNA Interference Has Cooled

By ANDREW POLLACK

When RNA interference first electrified biologists several years ago, pharmaceutical companies rushed to harness what looked like a swift and surefire way to develop new drugs.

Billions of dollars later, however, some of those same companies are now losing their enthusiasm for RNAi, as it is called. And that is raising doubts about how quickly, if at all, the Nobel Prize-winning technique for turning off specific genes will yield the promised bounty of innovative medicines.

The biggest bombshell was dropped in November, when the Swiss pharmaceutical giant Roche said it would end its efforts to develop drugs using RNAi, after it had invested half a billion dollars in the field over four years.

Just last week, as part of a broader research cutback, Pfizer decided to shut down its 100-person unit working on RNAi and related technologies. Abbott Laboratories has also quietly shelved its RNAi drug development work.

“In 2005 and 2006, there was a very sudden buildup of expectation that RNAi was going to cure many diseases in a very short time frame,” said Dr. Johannes Fruehauf, vice president for research at Aura Biosciences, a small company pursuing the field. “Some of the hype, I believe, is going away and a more realistic view is setting in.”

The issue is that while drugs working through the RNAi mechanism can indeed shut off genes, it has been difficult to deliver such drugs to the cells where they are needed. At a time when hard-pressed pharmaceutical companies are already scaling back research expenditures, RNAi is losing out to alternatives that seem closer to producing marketable drugs.

“I have no doubt that at a certain point in time RNAi will make it to the market,” said Klaus Stein, head of therapeutic modalities for Roche. But he added, “When we looked into this, we came to the conclusion that we have opportunities that have higher priorities.”

More here: Fever to Harness RNA Interference Cools – NYTimes.com.


Tags: , , , ,




Who Should Take Statins? The Debate Continues

Who Should Take Statins? The Debate Continues

By Alice Park, courtesy of TIME 

It is well known that the cholesterol-lowering drugs called statins can reduce the risk of heart attack among people who already have heart disease. But whether the medications can prevent a heart attack from occurring in the first place is still a hotly contested question among health experts.

Two new studies published on Monday in the Archives of Internal Medicine reignite the simmering debate.

One study revisits the merits of the controversial Jupiter trial (or Justification for the Use of Statins in Primary Prevention), which was published in 2008 in the New England Journal of Medicine. That trial concluded that the statin drug Crestor (rosuvastatin) lowered the combined risks of heart attack, stroke, other heart events or heart-related death by 47% in healthy patients with no history of heart problems or high cholesterol but high levels of C-reactive protein (CRP), a marker for inflammation. The findings prompted the Food and Drug Administration in February to expand the eligible patient population for Crestor by millions.

Critics of the Jupiter trial have contended that the benefits of the cholesterol drug may have been exaggerated because the trial was stopped early — after two years, instead of the planned five. Had the trial been allowed to continue, critics say, the differences in benefit between the treatment and placebo groups may have disappeared. That is the argument raised again by the new study in the Archives, by an international group of scientists led by Dr. Michel de Lorgeril at the University Joseph Fourier and the National Center of Scientific Research in Grenoble, France.

Jupiter was stopped prematurely when an independent monitoring board gleaned an overwhelming treatment benefit in the statin group. Although the early termination of randomized and blinded control studies is common — to ensure the safety of patients, study leaders frequently monitor the accruing data and stop the trial when one group shows a predetermined amount of benefit over the other — in Jupiter’s case, de Lorgeril’s group argues, the study never made clear what the predetermined benefit was.

What the data did show, however, is that when certain hard clinical endpoints — such as heart-related death — were considered, the difference between the two groups was not significant enough to warrant stopping the trial. Among the entire study population of more than 17,000, there was a total of only 240…
continue reading


Tags: , , , , ,




Pharmboy Takes On Lilly

Here’s Pharmboy’s first stock and options recommendation for the new year, or decade. He’s generally bullish on Lilly and presents two strategies – a simple buy/write strategy and a slightly more complicated strategy which includes selling puts and calls. - Ilene  

Pharmboy Takes On Lilly

Courtesy of Pharmboy

Another year has come and gone, 2010 (twenty ten or two thousand ten – which do you prefer?) is here. The market is great for some, and a baffling experience for others. One thing we do know is that we all need, at some point, health care in one form or another! This year, my write-ups may focus on longer term strategies so that we don’t have to manage our trades on a daily basis. This means a bit more depth in the analysis of companies we invest in, and perhaps some longer term picks.

So, here we go for Pharmboy’s first segment for a new decade!

Eli Lilly (LLY) – is a global pharmaceutical company and is a member of the Fortune 500.  Its global headquarters is located in Indianapolis, Indiana.  The company was founded in 1876 by a pharmaceutical chemist, Eli Lilly, after whom the company was ultimately named. The company’s first innovation was changing the flavorings of medicines so that they were easier to take. The business grew and in 2008, had of $20Billion.

Among the company’s major pharmaceutical breakthroughs are: cephalosporin (antibiotic), erythromycin (antibiotic), insulin, and fluoxetine (Prozac). Among other distinctions, Lilly is the world’s largest manufacturer and distributor of medications used in a broad range of psychiatric and mental health-related conditions, including clinical depression, generalized anxiety disorder, narcotic addiction, insomnia, bipolar disorder, schizophrenia, and others. Below is a list of their brands: 

Cancer
Alimta® (pemetrexed)
Gemzar® (gemcitabine hydrochloride)
Cardiology
Effient™ (prasugrel)
ReoPro® (abciximab)
Cardiology/Pulmonary
Adcirca™ (tadalafil)
Diabetes
Byetta® (exenatide) injection
Glucagon™ (glucagon for injection [rDNA origin])
Humulin® (human insulin [rDNA origin])
DISCONTINUED PRODUCT NOTICE:Humulin 50/50
Humalog® (insulin lispro injection [rDNA origin])
Humalog® Mix75/25™ (75% Insulin lispro protamine suspension, 25% insulin lispro injection [rDNA origin])
Humalog® Mix50/50™ (50% Insulin lispro protamine suspension, 50% insulin lispro injection [rDNA origin])
Diabetic Peripheral Neuropathic Pain (DPNP)
Cymbalta® (duloxetine hydrochloride)
Erectile Dysfunction
Cialis® (tadalafil)
Prozac Linked to Suicide Attempts and Violence

Fibromyalgia
Cymbalta® (duloxetine hydrochloride)
Growth Disorders


continue reading


Tags: , , , , , ,




Crazymaker: Journal of American Media and Lifestyle

Fun post for the evening, by Charles Hugh Smith, in case you missed it earlier. – Ilene

Crazymaker: Journal of American Media and Lifestyle

Courtesy of Charles Hugh Smith, Of Two Minds

If you wonder why our society is so schizophrenic--look no further than Crazymaker Journal.

I happened upon a fascinating new online publication: Crazymaker, the Journal of American Media and Lifestyle. I have to say the content set me back on my heels; rarely do I see such an honest portrayal of the carefully mixed messages dished out as "news" and "entertainment".

crazymaker journal

Gregory Bateson addressed how a cognitive "double bind" could create a schizophrenic state of anxiety and dysfunction.

Their findings indicated that the tangles in communication often diagnosed as schizophrenia are not necessarily result of an organic brain dysfunction. Instead, they found that destructive double binds were a frequent pattern of communication among families of patients, and they proposed that growing up amidst perpetual double binds could lead to learned patterns of confusion in thinking and communication.

Human communication is complex; 90% of it is nonverbal (see also Albert Mehrabian) and context is an essential part of it. Communication consists of the words said, tone of voice, and body language. It also includes how these relate to what has been said in the past; what is not said, but is implied; how these are modified by other nonverbal cues, such as the environment in which it is said, and so forth.

For example, if someone says "I love you," one takes into account who is saying it, their tone of voice and body language, and the context in which it is said. It may be a declaration of passion or a serene reaffirmation, insincere and/or manipulative, an implied demand for a response, a joke, its public or private context may affect its meaning, and so forth.

This is an apt description of the craziness created by media/marketing messages every minute of every hour of every day in the USA. Bake a super-rich cake, and oh my, why are you so fat? Now you have to torture yourself with diets which don’t work.

Girls: want to look hot and sexy? if you don’t, you’re a loathesome loser.

Guys: not ripped with bulging muscles? Too bad--you’re a loathesome loser, too. Image and exteriors are everything!

The media profits from selling marketing/adverts. Marketing
continue reading


Tags: , , , , , , , , , ,




 
 
 

Phil's Favorites

Morning News, 4-19-15

From Bloomberg:

Zhou Says China Has Room for Monetary Easing; May Not Use It

China’s central bank Governor Zhou Xiaochuan said the world’s second-largest economy has scope compared with other nations to ease its monetary policies though won’t necessarily take advantage of it. (Read more)

ECB’s Vasiliauskas Says Summer is Limit for Greek Emergency Cash

The European Central Bank shouldn’t extend Emergency Li...



more from Ilene

Zero Hedge

BillY KRiSTooL...

Courtesy of ZeroHedge. View original post here.

Submitted by williambanzai7.

.

 

The Founding  Principles of Neoclownism: 

 

1. Increase defense spending significantly if we are to carry out our global responsibi...



more from Tyler

All About Trends

Mid-Day Update

Reminder: David is available to chat with Members, comments are found below each post.

Click here for the full report.




To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David

Chart School

World Markets Weekend Update: The Rally Shifts (Mostly) Into Reverse

Courtesy of Doug Short.

Six of the eight indexes on our world watch list traded lower this week, with Germany's DAX down 5.57%. The best performing of the six losers was the S&P 500, down only 0.99%. The big positive outlier was China's Shanghai Composite, up a jaw-dropping 6.27% for the week and now up 32.54% in 2015. Hong Kong's Hang Seng was a less conspicuous outlier with a 1.40% weekly gain.

Here is an overlay of the eight for a sense of their comparative performance so far in 2015.

Here is a table of the 2015 data performance, sorted from high to low, along with the interim highs for the eight indexes. All eight indexes are in the green, with the top five gains ranging 12.62% to 32.54%. Not bad for for the first three-and-a-half months of the year. At the bottom of the list, the S&P 500 is up 1.08%.

...



more from Chart School

Kimble Charting Solutions

S&P 500 vulnerable to a decline says Joe Friday!

Courtesy of Chris Kimble.

CLICK ON CHART TO ENLARGE

When it comes to investing in the stock market, do you feel leadership can be important. If so, you might want to pay attention to price action from a key global stock index. China has been in the news for hot stock market performance that past couple of months. When it comes to the past couple of years, Germany has been stronger than China and the S&P 500. In the past two years the DAX index has gained 18% more than the S&P 500, which is a 60% greater return.

The chart below looks at conditions in the DAX at this time and what message is coming from this index.

...



more from Kimble C.S.

Sabrient

Sector Detector: Earnings and GDP temporarily take investor spotlight off the Fed

Reminder: Sabrient is available to chat with Members, comments are found below each post.

Courtesy of Sabrient Systems and Gradient Analytics

As we get into the heart of earnings season and anticipate the GDP report for Q1, the investor spotlight has been taken off the Federal Reserve and timing of its first interest rate hike, at least temporarily. Even though Q1 economic growth will undoubtedly look weak, the future remains bright for the U.S economy – even though many multinationals will struggle with top-line growth due to the strong dollar – and any near-term selloff resulting from weak economic or earnings news should be bought yet again in expectation of better results for the balance of the year. High sector correlations remain a concern, reflectin...



more from Sabrient

OpTrader

Swing trading portfolio - week of April 13th, 2015

Reminder: OpTrader is available to chat with Members, comments are found below each post.

 

This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



more from OpTrader

Digital Currencies

SkyNet Is Almost Sentient: HFTs To Start Trading Bitcoin

SkyNet Is Almost Sentient: HFTs To Start Trading Bitcoin

Courtesy of ZeroHedge. View original post here.

As noted earlier, with equities now a barren wasteland of volume (and liquidity), the last remaining HFT master (of whale order frontrunning) has been forced to go to those asset classes where organic flow is still abundant such as FX, courtesy of central banks engaged in global currency wars. However, HFTs rea...



more from Bitcoin

Promotions

Watch the Phil Davis Special on Money Talk on BNN TV!

Kim Parlee interviews Phil on Money Talk. Be sure to watch the replays if you missed the show live on Wednesday night (it was recorded on Monday). As usual, Phil provides an excellent program packed with macro analysis, important lessons and trading ideas. ~ Ilene

 

The replay is now available on BNN's website. For the three part series, click on the links below. 

Part 1 is here (discussing the macro outlook for the markets) Part 2 is here. (discussing our main trading strategies) Part 3 is here. (reviewing our pick of th...

more from Promotions

Market Shadows

Kimble Charts: South Korea's EWY

Kimble Charts: South Korea's EWY

By Ilene 

Chris Kimble likes the iShares MSCI South Korea Capped (EWY), but only if it breaks out of a pennant pattern. This South Korean equities ETF has underperformed the S&P 500 by 60% since 2011.

You're probably familiar with its largest holding, Samsung Electronics Co Ltd, and at least several other represented companies such as Hyundai Motor Co and Kia Motors Corp.

...



more from Paul

Mapping The Market

S&P 500 Leverage and Hedges Options - Part 2

Courtesy of Jean-Luc Saillard.

In my last post (Part 1 of this article), I looked at alternative ETFs that could be used as hedges against the corrections that we have seen during that long 2 year bull run. Looking at the results, it seems that for short (less than a month) corrections, a VIX ETF like VXX could actually be a viable candidate to hedge or speculate on the way down. Another alternative ETF was TMF, a long Treasuries ETF which banks on the fact that when markets go down, money tends to pack into treasuries viewed as safe instruments. In some cases, TMF even outperformed the usual hedging instruments like leveraged ETFs. There could of course be other factors at play since some of 2014 corrections were related to geopolitical events which are certain...

more from M.T.M.

Pharmboy

2015 - Biotech Fever

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

PSW Members - well, what a year for biotechs!   The Biotech Index (IBB) is up a whopping 40%, beating the S&P hands down!  The healthcare sector has had a number of high flying IPOs, and beat the Tech Sector in total nubmer of IPOs in the past 12 months.  What could go wrong?

Phil has given his Secret Santa Inflation Hedges for 2015, and since I have been trying to keep my head above water between work, PSW, and baseball with my boys...it is time that something is put together for PSW on biotechs in 2015.

Cancer and fibrosis remain two of the hottest areas for VC backed biotechs to invest their monies.  A number of companies have gone IPO which have drugs/technologies that fight cancer, includin...



more from Pharmboy

Help One Of Our Own PSW Members

"Hello PSW Members –

This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible.  Feel free to contact me directly at jennifersurovy@yahoo.com with any questions.

Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts.  After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.)  Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.

http://www.youcaring.com/medical-fundraiser/help-get-shadowfax-out-from-the-darkness-of-medical-bills-/126743

Thank you for you time!




FeedTheBull - Top Stock market and Finance Sites



About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>